Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to $70.6 million.

  • Fortress Biotech's Cash from Financing Activities rose 455.96% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.5 million, marking a year-over-year increase of 10.27%. This contributed to the annual value of $70.6 million for FY2024, which is 115.77% up from last year.
  • As of FY2024, Fortress Biotech's Cash from Financing Activities stood at $70.6 million, which was up 115.77% from $32.7 million recorded in FY2023.
  • Fortress Biotech's Cash from Financing Activities' 5-year high stood at $172.4 million during FY2020, with a 5-year trough of $32.7 million in FY2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $70.6 million (2024), whereas its average is $59.6 million.
  • In the last 5 years, Fortress Biotech's Cash from Financing Activities crashed by 56.53% in 2023 and then skyrocketed by 115.77% in 2024.
  • Yearly analysis of 5 years shows Fortress Biotech's Cash from Financing Activities stood at $172.4 million in 2020, then dropped by 13.58% to $149.0 million in 2021, then slumped by 49.45% to $75.3 million in 2022, then slumped by 56.53% to $32.7 million in 2023, then soared by 115.77% to $70.6 million in 2024.